Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.02

Mkt cap

6.9M

Volume

193K

High

1.09

P/E Ratio

-0.27

52-wk high

4.17

Low

1.00

Div yield

N/A

52-wk low

0.77

Adial Pharmaceuticals has commenced patient dosing in the second cohort following the successful completion of the first cohort.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:00 pm

Adial Pharmaceuticals has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This progress marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:00 pm

Adial Pharmaceuticals announced the publication of Phase 3 ONWARD study results in the European Journal of Internal Medicine, showing the efficacy of AD04 in reducing heavy drinking days among patients with specific genetic profiles. The study found minimal adverse events and high compliance, suggesting a promising treatment for alcohol use disorder.

Portfolio Pulse from Vandana Singh

June 20, 2024 | 12:00 pm

Adial Pharmaceuticals shares are trading higher after the company announced that the first patient has been dosed in its pharmacokinetics study of AD04 for Alcohol Use Disorder.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:40 pm

Adial Pharmaceuticals has dosed the first patient in a pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This marks a significant milestone in the development of AD04.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:31 pm

Adial Pharmaceuticals (NASDAQ:ADIL) has begun dosing patients in a pharmacokinetics study of AD04 for Alcohol Use Disorder. The study aims to optimize the design for a Phase 3 clinical trial and meet FDA requirements. Results are expected in early Q4 2024.

Portfolio Pulse from Vandana Singh

June 05, 2024 | 12:00 pm

The article highlights the performance of 12 healthcare stocks during Friday's after-market session. Sharps Technology (STSS) saw the highest gain with a 50.5% increase, while DIH Holding US (DHAI) experienced the largest drop, falling 24.4%.

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 8:31 pm

Adial Pharmaceuticals (NASDAQ:ADIL) reported a Q1 EPS of $(2.19), significantly missing the analyst consensus estimate of $(0.35) by 525.71%. This represents a 20.36% improvement over the $(2.75) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:45 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Processa Pharma led the gainers with a 31.2% increase, while Sunshine Biopharma experienced the largest drop among the losers, declining by 10.5%. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 12:06 pm

In Monday's pre-market session, health care stocks showed significant movement. Adial Pharmaceuticals (ADIL) and NKGen Biotech (NKGN) led the gainers with over 30% increases in their stock prices, while Vaxxinity (VAXX) and Hepion Pharmaceuticals (HEPA) were among the top losers, with VAXX stock dropping over 60%. The movements were attributed to various factors, including recent earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.